Company intelligence / Profile preview
EnduRx Pharmaceuticals
Tucson, Arizona, United Statesendurxpharm.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Preclinical
01
Overview
EnduRx has demonstrated significant tumor volume reductions—and sometimes complete elimination—in preclinical models using its peptide-directed nanoparticle technology. The company has received grant funding to advance its lead program toward IND-enabling studies, with ongoing collaborations to further validate the approach.
- Therapeutic areas
- OncologyCardiovascularOther
- Modalities
- Polymeric nanoparticles (peptide-directed)Macromolecule-based drug delivery systemsChemical drugs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Collaboration with MD Anderson Cancer Center on triple-negative breast cancer program funded by Department of Defense grant
Beyond the preview
Go deeper on EnduRx Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EnduRx Pharmaceuticals.